0:00
Gilead to transfer technology
Dr. Reddy’s Laboratories Ltd has entered into a non-exclusive Licensing Agreement with Gilead Sciences Inc on 13 June 2020, getting the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.
Dr. Reddy’s will receive technology transfer from Gilead for the manufacturing of this drug.
Dr. Reddy’s would need to do the manufacturing scale-up and obtain regulatory approval for marketing of this drug in respective countries.
Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (USFDA) to treat Covid-19. fiinews.com
